Article Versions Notes

Ahmed R, Muralidharan R, Amreddy N, Srivastava A, Mehta M, Panneerselvam J, de Castro RO, Berry WL, Ghosh S, Ragothaman M, et al. BRG1 (SMARCA4) Status Dictates the Response to EGFR Inhibitors in Wild-Type EGFR Non-Small Cell Lung Cancer. Cancers. 2026; 18(1):62. https://doi.org/10.3390/cancers18010062

Ahmed, Rebaz, Ranganayaki Muralidharan, Narsireddy Amreddy, Akhil Srivastava, Meghna Mehta, Janani Panneerselvam, Rodrigo Orlandini de Castro, William L. Berry, Susmita Ghosh, Murali Ragothaman, and et al. 2026. "BRG1 (SMARCA4) Status Dictates the Response to EGFR Inhibitors in Wild-Type EGFR Non-Small Cell Lung Cancer" Cancers 18, no. 1: 62. https://doi.org/10.3390/cancers18010062

Ahmed, R., Muralidharan, R., Amreddy, N., Srivastava, A., Mehta, M., Panneerselvam, J., de Castro, R. O., Berry, W. L., Ghosh, S., Ragothaman, M., Acharya, P., Zhao, Y. D., Pezza, R. J., Munshi, A., & Ramesh, R. (2026). BRG1 (SMARCA4) Status Dictates the Response to EGFR Inhibitors in Wild-Type EGFR Non-Small Cell Lung Cancer. Cancers, 18(1), 62. https://doi.org/10.3390/cancers18010062